This week the results of the PROMESA (Progression Rate Of Multiple system atrophy under EGCG Supplementation as Anti-aggregation-approach) study were published.

The PROMESA study was a clinical trial evaluating the impact of an experimental treatment called Epigallocatechin-gallate (or EGCG) on the progression of symptoms in people with Multiple System Atrophy (or MSA).

MSA is a condition very similar to Parkinson's - they share many common features, but MSA is considered to be a more progressive condition. EGCG is a naturally occuring compound that has previously demonstrated a powerful ability to inhibit protein aggregation in models of MSA and Parkinson's.

The study involved 64 people being divided into two groups (treatment and placebo) and they were evaluated over the 52 week trial. The investigators reported that while the treatment was well tolerated, there was no evidence of a difference between the two groups in their clinical motor scores at the end of the study.

CPT's deputy director of research, Dr Simon Stott says,

"This is disappointing news as there was hope of testing this compound in people with Parkinson's. EGCG was evaluated by The Cure Parkinson's Trust's Linked Clinical Trial committee in 2013, and there is considerable evidence demonstrating beneficial properties in models of Parkinson's."

Further reading: